Highlights
About
Monoclonal Antibody Treatment for Cancer and Inflammatory Diseases
Immune Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thereby helping to relieve associated inflammatory conditions. Immune Pharmaceuticals is currently conducting two phase-2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis. Bertilimumab may also have applications in other conditions including atopic dermatitis, asthma, and other eosinophil-mediated diseases.
Identity
| Name | Immune Pharmaceuticals |
|---|---|
| Slug | immune-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | immune-pharmaceuticals |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7V3OoIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Mar 2020 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Hillel St 24, Jerusalem, Israel |
Web & social
Classifications
Funding
| Total raised | $52.7M |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}